Abstract:Use of oral agents to treat gestational diabetes mellitus remains controversial. Recent recommendations from the Society for Maternal-Fetal Medicine assert that metformin may be a safe first-line alternative to insulin for gestational diabetes mellitus treatment and preferable to glyburide. However, several issues should give pause to the widespread adoption of metformin use during pregnancy. Fetal concentrations of metformin are equal to maternal, and metformin can inhibit growth, suppress mitochondrial respiration, have epigenetic modifications on gene expression, mimic fetal nutrient restriction, and alter postnatal gluconeogenic responses. Because both the placenta and fetus express metformin transporters and exhibit high mitochondrial activity, these properties raise important questions about developmental programming of metabolic disease in offspring. Animal studies have demonstrated that prenatal metformin exposure results in adverse long-term outcomes on body weight and metabolism. Two recent clinical randomized controlled trials in women with gestational diabetes mellitus or polycystic ovary syndrome provide evidence that metformin exposure in utero may produce a metabolic phenotype that increases childhood weight or obesity. These developmental programming effects challenge the conclusion that metformin is equivalent to insulin. Although the Society for Maternal-Fetal Medicine statement endorsed metformin over glyburide if oral agents are used, there are few studies directly comparing the 2 agents and it is not clear that metformin alone is superior to glyburide. Moreover, it should be noted that prior clinical studies have dosed glyburide in a manner inconsistent with its pharmacokinetic properties, resulting in poor glycemic control and high rates of maternal hypoglycemia. We concur with the American Diabetes Association and American Congress of Obstetricians and Gynecologists, which recommend insulin as the preferred agent, but we believe that it is premature to embrace metformin as equivalent to insulin or superior to glyburide. Due to the uncertainty of the long-term metabolic risks of either metformin or glyburide, we call for carefully controlled studies that optimize oral medication dosing according to their pharmacodynamic and pharmacokinetic properties in pregnancy, appropriately target medications based on individual patterns of hyperglycemia, and follow the offspring long-term for metabolic risk.

Metformin for Diabetes in Pregnancy: Are We Closer to Defining its Role?

Glycemic Control and Neonatal Outcomes in Women with Gestational Diabetes Mellitus Treated Using Glyburide, Metformin, or Insulin: A Pairwise and Network Meta-Analysis

Early Metformin in Gestational Diabetes

Metformin in gestational diabetes: physiological actions and clinical applications

Is metformin safe in pregnancy: a focus on offspring outcomes

Metformin in gestational diabetes: An emerging contender

Metformin Plus Insulin for Preexisting Diabetes or Gestational Diabetes in Early Pregnancy

Metformin in Gestational Diabetes Mellitus: To Use or Not to Use, That Is the Question

Metformin in the management of diabetes during pregnancy and lactation

The Role of Metformin in Metabolic Disturbances during Pregnancy: Polycystic Ovary Syndrome and Gestational Diabetes Mellitus

Treatment of Diabetes in Pregnancy With Metformin

A cautionary response to SMFM statement: pharmacological treatment of gestational diabetes

Research progress of metformin in gestational diabetes mellitus: a narrative review

Metformin – a Potentially Effective Drug for Gestational Diabetes Mellitus: a Systematic Review and Meta-Analysis

Comparative Efficacy and Safety of Metformin, Glyburide, and Insulin in Treating Gestational Diabetes Mellitus: A Meta-Analysis

Metformin versus Insulin in Treatment of Gestational Diabetes

Current Therapeutic Use of Metformin During Pregnancy: Maternal Changes, Postnatal Effects and Safety

Metformin and risk of adverse pregnancy outcomes among pregnant women with gestational diabetes in the United Kingdom: A population‐based cohort study

Metformin and Pregnancy Outcomes: Evidence Gaps and Unanswered Questions

Clinical Impact of Metformin Therapy on Gestational Diabetes Mellitus and Maternal-Infant Health Outcomes

Metformin Versus Insulin for Gestational Diabetes Mellitus: a Meta-Analysis